Skip to main content
LGND logo
LGND
(NASDAQ)
Ligand Pharmaceuticals Incorporated
$262.17-- (--)
Loading... - Market loading

Ligand Pharmaceuticals Incorporated (LGND) Stock Price & Financial Analysis

Ligand Pharmaceuticals Incorporated Stock Price Chart

Price Chart

Loading chart...

Financial Metrics & Key Statistics

Fundamental metrics, valuation ratios, and profitability indicators

Day's Range$245.00 - $272.79
52-Week High$276.20
52-Week Low$110.00
Open$267.73
Volume819.47K
Average Volume (3M)239.37K
Market Cap5.21B
Shares Outstanding19.88M
P/E Ratio (TTM)33.95
Price to Sales (P/S)18.99
Price to Book (P/B)5.23
EV/EBITDA24.97
Revenue (TTM)274.48M
Net Income (TTM)153.56M
Free Cash Flow (TTM)114.57M
EPS (TTM)$7.57
Profit Margin55.95%
Operating Margin37.18%
Return on Equity (ROE)15.40%
Debt to Equity0.45
50-Day MA$231.87
200-Day MA$201.88
52-Week Change129.83%
Annual Dividend$0.00
Dividend Yield0.00%
Payout Ratio0.00%
Last Dividend Ex-DateJul 2, 2010

Frequently Asked Questions About Ligand Pharmaceuticals Incorporated

What is the current stock price for LGND?

As of the latest trading session, LGND stock trades at $262.17. The 52-week range is $110.00–$276.20, with a day range of $245.00–$272.79.

What is the P/E ratio for LGND?

Ligand Pharmaceuticals Incorporated's trailing P/E ratio is 34.0, meaning investors pay $34.0 for every $1 of annual earnings. Ligand Pharmaceuticals Incorporated operates in the Healthcare sector.

Does LGND pay dividends?

Ligand Pharmaceuticals Incorporated does not currently pay a regular dividend. The company reinvests earnings into growth and operations. Check the Dividends tab for historical dividend information.

What do analysts recommend for LGND?

Based on 7 analysts, the consensus for LGND is Buy. The average 12-month price target is $NaN, representing a NaN% downside from the current price.

What is the market cap of LGND?

Ligand Pharmaceuticals Incorporated's market capitalization is $5.21B, classifying it as a mid-cap company. Ligand Pharmaceuticals Incorporated operates in the Healthcare sector within the Biotechnology industry.